<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00570908</url>
  </required_header>
  <id_info>
    <org_study_id>H-20924</org_study_id>
    <secondary_id>H 20924</secondary_id>
    <nct_id>NCT00570908</nct_id>
  </id_info>
  <brief_title>Brain Mets - Capecitabine Plus Sunitinib and WBRT</brief_title>
  <official_title>A Phase 2 Trial of Capecitabine Concomitantly With Whole Brain Radiotherapy(WBRT) Followed by Capecitabine and Sunitinib for Central Nervous System, (CNS) Metastases in Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor Breast Care Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baylor Breast Care Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of concurrent whole brain&#xD;
      radiotherapy (WBRT) and capecitabine followed by combination capecitabine and sunitinib in&#xD;
      treating patients with CNS metastases from breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Central nervous system (CNS) metastases is the most common type of brain malignancy, and&#xD;
      breast cancer is the second most common type of malignancy to cause CNS metastases. Although&#xD;
      the incidence of CNS metastases is less common than bone or visceral metastases, it is&#xD;
      associated with poorer prognosis and is relatively unresponsive to systemic therapies. The&#xD;
      incidence of CNS metastases in breast cancer has been estimated as 1-16% in clinical series,&#xD;
      with higher rates (18-30%) in autopsy series. Recently a trend towards increasing CNS relapse&#xD;
      has been noted, up to 25-34%. This may be partly explained by the increasing use of&#xD;
      contrast-enhanced magnetic resonance imaging (MRI), heightened awareness by patient or&#xD;
      clinicians, or an alteration in the natural history of breast cancer with improvements in&#xD;
      systemic therapies, resulting in a prolongation of survival. Therefore, with improvements in&#xD;
      treatments, metastases are better controlled, resulting in the CNS becoming a sanctuary for&#xD;
      residual disease. The treatment of CNS metastases in breast cancer remains challenging.&#xD;
      Surgical resection of tumor will prolong survival only in patients with a single lesion and&#xD;
      with well controlled systemic disease. For patients with multiple lesions, whole brain&#xD;
      radiotherapy (WBRT) remains the backbone in the management of CNS metastases. Recently the&#xD;
      use of stereotactic radiosurgery alone or in combination with WBRT has been explored.&#xD;
      Although better local control was achieved with the combination therapy, minimal overall&#xD;
      survival benefit was seen. This may be secondary to the competing risk of death from systemic&#xD;
      (extra-CNS) progression. The use of systemic agents including chemotherapy and hormonal&#xD;
      therapy has been generally disappointing. This is often attributed to the impermeability of&#xD;
      the blood-brain and blood-tumor barriers. Furthermore, P-glycoprotein (Pgp), a drug efflux&#xD;
      pump encoded by the multidrug resistance gene, mdR1, is expressed in brain endothelial cells.&#xD;
      Therefore, agents such as doxorubicin, cyclophosphamide, 5-fluorouracil, paclitaxel,&#xD;
      docetaxel and vinorelbine, which are active against breast cancer, may either penetrate CNS&#xD;
      poorly, or be transported out of the CNS environment. However, the blood brain barrier may be&#xD;
      more leaky and permeable than previously thought in patients with CNS metastases, and these&#xD;
      agents may achieve therapeutic concentrations in the CNS. As evidence for this, patients&#xD;
      without prior exposure to agents such as cyclophosphamide, methotrexate, 5-fluorouracil,&#xD;
      vincristine, and doxorubicin, can have significant objective responses in the CNS metastases.&#xD;
      Today, most patients would have received these agents in the adjuvant setting, thus&#xD;
      emphasizing the importance of both chemo-sensitivity together with CNS penetration, in the&#xD;
      treatment of CNS metastases.&#xD;
&#xD;
      This is a single arm, open label, phase II drug study. This study will be conducted at the&#xD;
      Breast Care Center at Baylor College of Medicine and its affiliated hospital, and at Ben Taub&#xD;
      General Hospital in Houston. Patients who were diagnosed with CNS metastases (brain +/-&#xD;
      leptomeningeal disease) will be identified prospectively. All eligible patients will receive&#xD;
      capecitabine concurrently with WBRT followed by combination capecitabine with sunitinib. WBRT&#xD;
      will be administered at 30 Gy in 10 fractions together with capecitabine to be given on the&#xD;
      first day of WBRT at 1000 mg/m2/day and continued daily for 14 days. After a 7 days rest&#xD;
      period, capecitabine will be restarted at 2000mg/m2/day for 14 days followed by a 7 days rest&#xD;
      period. This will be given together with sunitinib at 37.5 mg daily. This is the dosing&#xD;
      determined by the phase I study with capecitabine and sunitinib. Dose reduction and/or&#xD;
      treatment postponement will be done for significant toxicity. Capecitabine with sunitinib&#xD;
      will be administered until disease progression in either CNS and/or non-CNS sites. Efficacy&#xD;
      assessments will be performed on all subjects via imaging studies in the CNS and extra-CNS&#xD;
      sites 8 weeks after starting study, then every 12 weekly. Neurological examination will be&#xD;
      performed at baseline, 3 weeks after starting treatment, then every 6 weekly. Assessment of&#xD;
      treatment toxicity will be performed at baseline, 3 weeks after starting treatment, then&#xD;
      every 3 weekly using the NCI Common Toxicity grading system. Clinical and laboratory&#xD;
      parameters will be assessed until disease progression or withdrawal from study (due to&#xD;
      unacceptable toxicity or withdrawal of consent). Subjects with progression of CNS and / or&#xD;
      extra-CNS disease will be considered progressors. Subjects withdrawn from treatment will be&#xD;
      followed for survival until death.&#xD;
&#xD;
      Primary endpoint: 1. To determine progression free survival. Progression will be defined by&#xD;
      progression in either CNS or extra-CNS metastases. Secondary endpoint: 1. To assess the&#xD;
      toxicities associated with the regimen 2. To determine the overall objective response in CNS&#xD;
      disease 3. To determine the overall objective response in extra-CNS disease 4. To determine&#xD;
      the overall survival.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to poor accrual this study is being closed to accrual&#xD;
  </why_stopped>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>2 years</time_frame>
    <description>Progression free survival is defined as form initiation of WBRT with capecitabine to the time of first documented progression at any site (CNS or non-CNS site) or death due to any cause, where progression is defined stringently by progression in either CNS or extra-CNS metastases.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Study Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>capecitabine administered concurrently with WBRT followed by combination the combination of capecitabine with sunitinib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sunitinib</intervention_name>
    <description>Sutent</description>
    <arm_group_label>Study Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
    <description>concurrently</description>
    <arm_group_label>Study Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>WBRT</intervention_name>
    <description>Whole Brain Radiotherapy 30 Gy in 10 fractions</description>
    <arm_group_label>Study Group</arm_group_label>
    <other_name>Whole Brain Radiotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients must be age 18 or older. Histological or cytologically confirmed invasive breast&#xD;
        cancer, with Stage IV disease.&#xD;
&#xD;
        Evidence of radiographically measurable CNS metastases (greater than or equal to 10mm on&#xD;
        T1-weighted gadolinium-enhanced MRI) within 2 weeks prior to starting treatment. Patients&#xD;
        without known extra-CNS disease are eligible.&#xD;
&#xD;
        Must have metastases in the brain. Patients with concurrent leptomeningeal carcinomatosis&#xD;
        are eligible for the study. Local radiation to sites of meningeal involvement in the spine&#xD;
        is allowed.&#xD;
&#xD;
        No prior whole brain radiation. Patients who had previous stereotactic brain irradiation&#xD;
        are eligible, provided they have new measurable brain lesions (which has not been radiated&#xD;
        previously) and will receive WBRT at 30Gy over 10 fractions.&#xD;
&#xD;
        May undergo surgical resection of CNS metastases if clinically indicated, but must have&#xD;
        remaining measurable disease in the brain after surgery.&#xD;
&#xD;
        No prior treatment with capecitabine in the adjuvant or metastatic settings. Patients may&#xD;
        have completed 5-fluorouracil based treatment in the adjuvant setting or metastatic setting&#xD;
        more than one year prior.&#xD;
&#xD;
        Patients who had previous trastuzumab therapy will be eligible but treatment will be&#xD;
        discontinued prior to enrollment.&#xD;
&#xD;
        Cardiac ejection fraction within institutional range of normal as measure by echocardiogram&#xD;
        or MUGA scans at baseline.&#xD;
&#xD;
        Hematological adequacy Hepatic adequacy Renal adequacy Must have recovered from toxicity of&#xD;
        prior chemotherapy with laboratory values as specified above. Concurrent treatment with&#xD;
        bisphosphonates is permitted. Performance status of ECOG 0-1.&#xD;
&#xD;
        Life expectancy of at least 12 weeks. At least 3 weeks since major surgical procedures.&#xD;
        Able to swallow and retain oral medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Pregnant or breast feeding. Known allergy to capecitabine or 5-fluorouracil. Known to have&#xD;
        dihydropyrimidine dehydrogenase (DPD) deficiency.&#xD;
&#xD;
        Patients who have leptomeningeal carcinomatosis as the only site of CNS metastases.&#xD;
&#xD;
        Patients taking concomitant medications which are CYP3A4 inhibitors or inducers.&#xD;
&#xD;
        Patients who will receive intrathecal chemotherapy for leptomeningeal disease. Patients&#xD;
        with psychiatric or addictive disorders that would adversely effect compliance with oral&#xD;
        medication.&#xD;
&#xD;
        Life expectancy less than 3 months. Symptomatic lymphangitic spread to lung. Malabsorption&#xD;
        syndrome, disease significantly affecting gastrointestinal function, or resection of the&#xD;
        stomach or small bowel.&#xD;
&#xD;
        History of immediate or delayed hypersensitivity reaction to gadolinium contrast agents, or&#xD;
        other contraindication or gadolinium contrast.&#xD;
&#xD;
        Other known contraindication to MRI, such as a cardiac pacemaker, implanted cardiac&#xD;
        defibrillator, brain aneurysm clips, cochlear implant, ocular foreign body, or shrapnel,&#xD;
&#xD;
        1Vascular disease within 12 months prior to enrollment Uncontrolled infection History of&#xD;
        other malignancy, except for curatively treated basal cell carcinoma or squamous cell&#xD;
        carcinoma of the skin, or carcinoma in situ of the cervix. Subjects with other malignancies&#xD;
        who have been disease-free for at least 5 years are eligible&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mothaffar' Rimawi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine, Breast Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lester and Sue Smith Breast Center at Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <study_first_submitted>December 7, 2007</study_first_submitted>
  <study_first_submitted_qc>December 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2007</study_first_posted>
  <results_first_submitted>July 22, 2014</results_first_submitted>
  <results_first_submitted_qc>July 22, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 12, 2014</results_first_posted>
  <last_update_submitted>September 8, 2014</last_update_submitted>
  <last_update_submitted_qc>September 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>brain metastasis</keyword>
  <keyword>breast cancer</keyword>
  <keyword>metastatic breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>WBRT + Capecitabine + Sunitinib</title>
          <description>capecitabine concurrently with WBRT(Whole Brain Radiotherapy 30 Gy in 10 fractions) followed by combination capecitabine with sunitinib(Sutent)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5">5 patients progressed during the study treatment</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>12 patients were enrolled and started treatment</population>
      <group_list>
        <group group_id="B1">
          <title>WBRT + Capecitabine + Sunitinib</title>
          <description>capecitabine concurrently with WBRT(Whole Brain Radiotherapy 30 Gy in 10 fractions) followed by combination capecitabine with sunitinib(Sutent)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50" lower_limit="32" upper_limit="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival</title>
        <description>Progression free survival is defined as form initiation of WBRT with capecitabine to the time of first documented progression at any site (CNS or non-CNS site) or death due to any cause, where progression is defined stringently by progression in either CNS or extra-CNS metastases.</description>
        <time_frame>2 years</time_frame>
        <population>5 patients progressed during the study treatment. 7 patients were off study treatment early due to AE or withdrawal but 6 of them were followed for the survival outcome, 1 was lost to follow up after 3.5 months observation (censored data).</population>
        <group_list>
          <group group_id="O1">
            <title>WBRT + Capecitabine + Sunitinib</title>
            <description>capecitabine concurrently with WBRT(Whole Brain Radiotherapy 30 Gy in 10 fractions) followed by combination capecitabine with sunitinib(Sutent)</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival</title>
          <description>Progression free survival is defined as form initiation of WBRT with capecitabine to the time of first documented progression at any site (CNS or non-CNS site) or death due to any cause, where progression is defined stringently by progression in either CNS or extra-CNS metastases.</description>
          <population>5 patients progressed during the study treatment. 7 patients were off study treatment early due to AE or withdrawal but 6 of them were followed for the survival outcome, 1 was lost to follow up after 3.5 months observation (censored data).</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" lower_limit="2.1" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>WBRT + Capecitabine + Sunitinib</title>
          <description>capecitabine concurrently with WBRT(Whole Brain Radiotherapy 30 Gy in 10 fractions) followed by combination capecitabine with sunitinib(Sutent)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac - CHF</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Diabetetic Ketoacidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea (SOB)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>ANC low</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Gums - Bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hemolysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Low WBC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>TSH</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision - Flashing Lights</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Mucositis - Oral</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Oral Thrush</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatifue</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="13" subjects_affected="6" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>E. Coli Bacteremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Infection - Middle Ear</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Infection - Sinus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Alkaline Phosphate</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>AST</sub_title>
                <counts group_id="E1" events="11" subjects_affected="6" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Bilirubin, Elevated</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Leukocytes</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>ALT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypernaturia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bilateral Pedal Edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Pain - Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mood Alteration - Depression</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Frequency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hand-Foot Skin Reaction</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Erythema - Right Axillary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Rash - Leg</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Yellow skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Mothaffar Rimawi</name_or_title>
      <organization>Baylor Coolege of Medicine</organization>
      <phone>7137981811</phone>
      <email>rimawi@bcm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

